ReviewBioengineering & translational medicine2026
Engineering ovarian tissue via biofabrication and 3D bioprinting: Challenges and emerging perspectives.
Review in Bioengineering & translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of bioprosthetic ovaries using advanced biofabrication and 3D bioprinting technologies has achieved significant attention in recent years. This work begins with an analysis of ovarian anatomy and physiology, emphasizing the critical structural and functional components that must be replicated for an effective engineered in vitro model. It further outlines the principles and capabilities of 3D bioprinting, with a focus on the customization of printing modalities and bioinks to closely mimic native ovarian tissue. Given the ovary's dual functions in gametogenesis and endocrine signaling, attention is given to how engineered constructs can be designed to restore hormonal homeostasis through the precise spatial arrangement and biological activity of embedded cells. Finally, the technical challenges and ethical considerations associated with translating bioprinted ovarian tissues into clinical applications are discussed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.